莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期的效果比较
|
摘要
目的:比较莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期的效果。方法:选取90例慢性阻塞性肺疾病急性加重期患者作为观察对象,按照随机数字表法将其分为观察组和对照组各45例。对照组给予左氧氟沙星治疗,观察组给予莫西沙星治疗。比较两组治疗总有效率、肺功能水平、炎症因子水平以及不良反应发生率。结果:观察组临床治疗总有效率为97.78%(44/45)、明显高于对照组的82.22%(37/45),观察组不良反应发生率为2.22%(1/45)、明显低于对照组的15.55%(7/45),差异均有统计学意义(P<0.05);两组患者治疗前FEV1、FEV1/FVC水平的对比,差异无统计学意义(P>0.05);治疗后两组患者FEV1、FEV1/FVC水平明显高于治疗前,差异有统计学意义(P<0.05);且观察组患者治疗后FEV1、FEV1/FVC水平明显比对照组高,差异有统计学意义(P<0.05);两组患者治疗前CRP、IL-8、TNF-α、PA水平的对比,差异无统计学意义(P>0.05);治疗后两组患者CRP、IL-8、TNF-α、PA水平明显优于治疗前,差异有统计学意义(P<0.05);且观察组患者治疗后CRP、IL-8、TNF-α、PA水平优于对照组,差异有统计学意义(P<0.05)。结论:与左氧氟沙星相比,采用莫西沙星治疗慢性阻塞性肺疾病急性加重期的效果更好,且不良反应少。
Objective: To compare effects of Moxifloxacin and Levofloxacin in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: Ninety patients with acute exacerbation of chronic obstructive pulmonary disease were selected as observation subjects. They were divided into observation group and control group according to random number table method. The control group was treated with Levofloxacin, while the observation group was given Moxifloxacin. The total effective rate, lung function, inflammatory factor level and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 97.78%(44/45), which was significantly higher than 82.22%(37/45) of the control group, the incidence of adverse reactions in the observation group was 2.22%(1/45), which was significantly lower than that in the control group of 15.55%(7/45), and the differences were statistically significant(P<0.05). There were no statistical differences in the FEV1 and FEV1/FVC levels between the two groups before the treatment(P>0.05). However, the FEV1 and FEV1/FVC levels of the two groups after the treatment were significantly higher than those before the treatment(P<0.05), and those of the observation group were significantly higher than those of the control group after the treatment(P<0.05). There were no statistical differences in the CRP, IL-8, TNF-α and PA levels between the two groups before the treatment(P>0.05). However, the CRP, IL-8, TNF-α and PA levels of the two groups after the treatment were significantly better than those before the treatment(P<0.05), and those of the observation group were significantly better than those of the control group after the treatment(P<0.05). Conclusions: Moxifloxacin is more effective than Levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease.
Objective: To compare effects of Moxifloxacin and Levofloxacin in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: Ninety patients with acute exacerbation of chronic obstructive pulmonary disease were selected as observation subjects. They were divided into observation group and control group according to random number table method. The control group was treated with Levofloxacin, while the observation group was given Moxifloxacin. The total effective rate, lung function, inflammatory factor level and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 97.78%(44/45), which was significantly higher than 82.22%(37/45) of the control group, the incidence of adverse reactions in the observation group was 2.22%(1/45), which was significantly lower than that in the control group of 15.55%(7/45), and the differences were statistically significant(P<0.05). There were no statistical differences in the FEV1 and FEV1/FVC levels between the two groups before the treatment(P>0.05). However, the FEV1 and FEV1/FVC levels of the two groups after the treatment were significantly higher than those before the treatment(P<0.05), and those of the observation group were significantly higher than those of the control group after the treatment(P<0.05). There were no statistical differences in the CRP, IL-8, TNF-α and PA levels between the two groups before the treatment(P>0.05). However, the CRP, IL-8, TNF-α and PA levels of the two groups after the treatment were significantly better than those before the treatment(P<0.05), and those of the observation group were significantly better than those of the control group after the treatment(P<0.05). Conclusions: Moxifloxacin is more effective than Levofloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease.
引文
[1]齐慧生,刘宝欣,郭红,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病感染性肺炎的疗效与安全性研究[J].中华医院感染学杂志,2016,26(9):1967-1969.
[2]李冰冰,李维,白雪.莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期治疗效果分析[J].航空航天医学杂志,2017,28(5):599-601.
[3]龙婷华.莫西沙星与左氧氟沙星序贯治疗慢性阻塞性肺疾病急性发作的对比研究[J].北方药学,2016,13(7):119-120.
[4]陈政. COPD合并感染性肺炎患者联合应用美罗培南与莫西沙星的疗效及不良反应分析[J].中国民康医学,2017,29(11):20-22.
[5]武光瑞.慢性阻塞性肺疾病急性加重期应用莫西沙星和左氧氟沙星治疗的效果和安全性分析[J].吉林医学,2016,37(12):2991-2992.
[6]柯剑辉.莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床效果观察[J].临床合理用药杂志,2017,10(1):66-67.
[7]宋迪,谢华,刘美岑.合并糖尿病对慢性阻塞性肺疾病急性发作患者病原学影响[J].西南国防医药,2017,27(10):1093-1095.
[8]张东升,李剑波.莫西沙星替代左氧氟沙星治疗耐多药肺结核疗效分析[J].疾病监测与控制,2016,10(9):756-757.
[9]艾合提热木·塔力甫,刘甚红.班布特罗联合莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2016,31(10):1555-1558.
[2]李冰冰,李维,白雪.莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期治疗效果分析[J].航空航天医学杂志,2017,28(5):599-601.
[3]龙婷华.莫西沙星与左氧氟沙星序贯治疗慢性阻塞性肺疾病急性发作的对比研究[J].北方药学,2016,13(7):119-120.
[4]陈政. COPD合并感染性肺炎患者联合应用美罗培南与莫西沙星的疗效及不良反应分析[J].中国民康医学,2017,29(11):20-22.
[5]武光瑞.慢性阻塞性肺疾病急性加重期应用莫西沙星和左氧氟沙星治疗的效果和安全性分析[J].吉林医学,2016,37(12):2991-2992.
[6]柯剑辉.莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床效果观察[J].临床合理用药杂志,2017,10(1):66-67.
[7]宋迪,谢华,刘美岑.合并糖尿病对慢性阻塞性肺疾病急性发作患者病原学影响[J].西南国防医药,2017,27(10):1093-1095.
[8]张东升,李剑波.莫西沙星替代左氧氟沙星治疗耐多药肺结核疗效分析[J].疾病监测与控制,2016,10(9):756-757.
[9]艾合提热木·塔力甫,刘甚红.班布特罗联合莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2016,31(10):1555-1558.